Market Overview:
The global rituximab drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hematological cancers, autoimmune diseases, and organ transplants. Additionally, the increasing demand for rituximab drugs due to their high efficacy and safety profiles is also contributing to the growth of this market. Based on type, the global rituximab drug market can be segmented into 10ml and 50ml segments. The 10ml segment is expected to account for a larger share of this market than the 50ml segment during the forecast period owing to its lower price point and ease of use. Based on application, the global rituximab drug market can be divided into hematological cancers, autoimmune diseases, and organ transplants segments.
Product Definition:
A monoclonal antibody used to treat cancer, autoimmune diseases, and other conditions. Rituximab binds to a protein on the surface of B cells called CD20, which causes the cells to die. It is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), Wegener's granulomatosis, and idiopathic thrombocytopenic purpura (ITP).
10ml:
Rituximab is a chimeric monoclonal antibody that binds to the CD20 antigen. It was approved by the FDA in 2006 for treatment of B-cell acute lymphoblastic leukemia and in 2007 for Rheumatoid Arthritis. The drug has also received approval from European Medicines Agency (EMA) and Japanese Ministry of Health, Labor & Welfare (MHLW) for use as an anti-CD20 therapeutic product.
50ml:
Rituximab (Rixrimab) is a prescription medicine used for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and associated symptoms, such as pain in feet and legs, weakness, and difficulty with walking. The medicine works by blocking the B7-1 Ligand which helps to reduce immune response to the nerves.
50ml is a vial containing solution for Rituximab injection.
Application Insights:
Rituximab is used for the treatment of various diseases, such as rheumatoid arthritis, ankylosing spondylitis, Crohn¢â‚¬â„¢s disease and psoriasis. The product finds application in the treatment of rheumatoid arthritis as it reduces inflammation in the body. It does this by inhibiting tumor necrosis factor alpha (TNF-alpha) activity. TNF-alpha is a key cytokine that plays a major role in Inflammatory Bowel Diseases (IBDs). Rituximab also has usage for other autoimmune conditions such as psoriatic arthritis and uveitis due to its ability to reduce inflammation.
The use of rituximab for treating cancerous tumors leads to reduced levels of tumor necrosis factor alpha (TNF-alpha).
Regional Analysis:
North America dominated the global rituximab drug market in 2017. This is attributed to the presence of key players, such as Pfizer Inc.; and Biogen Inc., in this region. Moreover, approval of rituximab for marketing in U.S.
On the other hand, Asia Pacific region is expected to grow at a lucrative rate over the forecast period owing to increasing prevalence of B cell chronic lymphocytic leukemia (BCLCL) and T-cell acute lymphocytic leukemia (TALL).
Growth Factors:
- Increasing incidence of autoimmune diseases: The global prevalence of autoimmune diseases is increasing at an alarming rate. This is primarily attributed to the changing lifestyles and environmental factors. The growing awareness about the available treatment options for autoimmune diseases is also propelling the demand for rituximab drugs.
- Rising geriatric population: The global geriatric population is expanding rapidly due to the increase in life expectancy and declining fertility rates across the world. This is leading to an increase in the number of patients suffering from age-related disorders such as cancer, arthritis, and multiple sclerosis, which are treated with rituximab drugs.
- Technological advancements in rituximab drug development: Pharmaceutical companies are investing heavily in research and development activities to develop innovative therapies for various indications using rituximab drugs. This has resulted in significant technological advancements in this field, which is aiding wider patient access to these medications globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Rituximab Drug Market Research Report
By Type
10ml, 50ml
By Application
Hematological Cancers, Autoimmune Diseases, Organ Transplants
By Companies
Roche, Roche
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Rituximab Drug Market Report Segments:
The global Rituximab Drug market is segmented on the basis of:
Types
10ml, 50ml
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hematological Cancers, Autoimmune Diseases, Organ Transplants
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Roche
Highlights of The Rituximab Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10ml
- 50ml
- By Application:
- Hematological Cancers
- Autoimmune Diseases
- Organ Transplants
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rituximab Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rituximab is a drug used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major companies in the rituximab drug market are Roche, Roche.
The rituximab drug market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rituximab Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Rituximab Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Rituximab Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Rituximab Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Rituximab Drug Market Size & Forecast, 2020-2028
4.5.1 Rituximab Drug Market Size and Y-o-Y Growth
4.5.2 Rituximab Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 10ml
5.2.2 50ml
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hematological Cancers
6.2.2 Autoimmune Diseases
6.2.3 Organ Transplants
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rituximab Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rituximab Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 10ml
9.6.2 50ml
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hematological Cancers
9.10.2 Autoimmune Diseases
9.10.3 Organ Transplants
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 10ml
10.6.2 50ml
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hematological Cancers
10.10.2 Autoimmune Diseases
10.10.3 Organ Transplants
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 10ml
11.6.2 50ml
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hematological Cancers
11.10.2 Autoimmune Diseases
11.10.3 Organ Transplants
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 10ml
12.6.2 50ml
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hematological Cancers
12.10.2 Autoimmune Diseases
12.10.3 Organ Transplants
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 10ml
13.6.2 50ml
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hematological Cancers
13.10.2 Autoimmune Diseases
13.10.3 Organ Transplants
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rituximab Drug Market: Competitive Dashboard
14.2 Global Rituximab Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Roche
